UnitedHealth Group Incorporated (UNH) Cash Flow Statement

The consistent OCF/NI ratio above 1.0, except for 2025Q1 and 2024Q4, suggests that underwriting cash generation is strong, with premiums collected outpacing claims paid. This float provides a stable source of investment income, though the 2025Q4 dip to $1.1B OCF against $94.7B claims highlights potential timing mismatches that warrant monitoring.

The sharp increase in claims payments, particularly in 2025Q4, suggests that medical cost inflation is accelerating, consuming a larger share of premium cash inflows. This trend, if sustained, could pressure underwriting margins and reduce the float available for investment, aligning with the prior income statement analysis showing a loss ratio spike to 83.7%.

The modest investment activity suggests that UNH is not actively rebalancing its portfolio, possibly due to stable cash flows from operations. However, the $12.8B purchase in 2025Q4, offset by $14.1B in sales, may indicate opportunistic adjustments, but overall, investment income remains a minor contributor to cash generation.

The dividend and buyback payments are well within operating cash flow, suggesting that capital return is not reliant on portfolio liquidation. However, the variability in buyback activity—zero in 2026Q1 and 2024Q2—may indicate a cautious approach to capital allocation amid medical cost uncertainty.

The persistent OCF/NI ratio above 1.0, except in loss-making quarters, implies that reported earnings understate cash generation, possibly due to reserve releases or non-cash expenses. This divergence may indicate that earnings quality is high, but investors should monitor whether reserve releases are masking underlying deterioration in claims experience.